Last reviewed · How we verify
NCT04641936
Urine Omics Predicting IO Therapy Responses in mUC Patients
trial testing No intervention required in Metastatic Urothelial Carcinoma in 600 participants. Currently enrolling.
31 October 2025
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 17 December 2020 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2027 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- No intervention required
Conditions studied
- Metastatic Urothelial Carcinoma — all drugs for Metastatic Urothelial Carcinoma →
Sponsor
National Taiwan University Hospital
Who can join
20 and older, male only, with Metastatic Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research.
Ahmed M, Semreen AM, El-Huneidi W, Bustanji Y, et al · · 2022 · cited 16× · PMID 36613792 · DOI 10.3390/ijms24010348
Verify or expand the search:
- PubMed search for NCT04641936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention required
Trials testing the same drug.
- NCT04712305 — Urine Omics Predicting IO Therapy Responses in mRCC Patients · recruiting
- NCT03237026 — Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients · recruiting
Other recruiting trials for Metastatic Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting
- NCT06524544 — A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of · Phase 3 · recruiting
- NCT06862219 — A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer · Phase 4 · recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04641936 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04641936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing